Search

everythinglearnresearchcommunity

for

Search:↓

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Bicalutamide shows promise for treating female hair loss.

Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.

Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.

Flutamide rarely causes liver toxicity in prostate cancer patients.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.

Dutasteride is more effective than finasteride for hair growth with similar side effects.

Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.

Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.

5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

Two teenage boys lost hair after taking a drug for growth, which was not a known side effect for kids.

The combination of arginine and zinc reduces hair loss and increases hair growth effectively.

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.

Adjusting minoxidil dosage may be safer than using bicalutamide for hair loss in women.

Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.

A woman's hair loss was probably caused by the antifungal drug anidulafungin.

Bicalutamide may improve hair growth in postmenopausal women with mild side effects.

Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.

Cyproterone acetate may cause liver cancer at high doses, but is considered safe at recommended doses for approved uses.

A man developed hair loss from testosterone treatment but improved with additional medication.

Dutasteride for hair loss can cause skin reactions like itchy red plaques.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.

Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.